[English] 日本語
Yorodumi Papers
- Database of articles cited by EMDB/PDB/SASBDB data -

+
Search query

Keywords
Structure methods
Author
Journal
IF

-
Structure paper

TitleStructure-guided optimization of novel CDK2 inhibitors discovered by high-throughput screening
Journal, issue, pagesTo be Published
Publish dateFeb 2, 2011 (structure data deposition date)
AuthorsSchonbrunn, E. / Becker, A. / Betzi, S. / Alam, R. / Han, H. / Rawle, F. / Katta, V. / Jakkaraj, J. / Chakrasali, R. / Neelam, S. ...Schonbrunn, E. / Becker, A. / Betzi, S. / Alam, R. / Han, H. / Rawle, F. / Katta, V. / Jakkaraj, J. / Chakrasali, R. / Neelam, S. / Hook, D. / Tash, J. / Georg, G.
External linksSearch PubMed
MethodsX-ray diffraction
Resolution1.6 - 2 Å
Structure data

PDB-3ql8:
CDK2 in complex with inhibitor JWS-6-260
Method: X-RAY DIFFRACTION / Resolution: 1.9 Å

PDB-3qqf:
CDK2 in complex with inhibitor L1
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3qqg:
CDK2 in complex with inhibitor L2-5
Method: X-RAY DIFFRACTION / Resolution: 1.9 Å

PDB-3qqh:
CDK2 in complex with inhibitor L2-2
Method: X-RAY DIFFRACTION / Resolution: 1.87 Å

PDB-3qqj:
CDK2 in complex with inhibitor L2
Method: X-RAY DIFFRACTION / Resolution: 1.7 Å

PDB-3qql:
CDK2 in complex with inhibitor L3
Method: X-RAY DIFFRACTION / Resolution: 1.85 Å

PDB-3qrt:
CDK2 in complex with inhibitor NSK-MC2-55
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3qru:
CDK2 in complex with inhibitor NSK-MC1-12
Method: X-RAY DIFFRACTION / Resolution: 1.95 Å

PDB-3qwj:
CDK2 in complex with inhibitor KVR-1-142
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3qwk:
CDK2 in complex with inhibitor KVR-1-150
Method: X-RAY DIFFRACTION / Resolution: 1.85 Å

PDB-3qx2:
CDK2 in complex with inhibitor KVR-1-190
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3qx4:
CDK2 in complex with inhibitor KVR-1-78
Method: X-RAY DIFFRACTION / Resolution: 1.92 Å

PDB-3qxo:
CDK2 in complex with inhibitor KVR-1-84
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3qzf:
CDK2 in complex with inhibitor JWS-6-52
Method: X-RAY DIFFRACTION / Resolution: 2 Å

PDB-3qzg:
CDK2 in complex with inhibitor JWS-6-76
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3qzh:
CDK2 in complex with inhibitor KVR-1-124
Method: X-RAY DIFFRACTION / Resolution: 1.95 Å

PDB-3qzi:
CDK2 in complex with inhibitor KVR-1-126
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3r1q:
CDK2 in complex with inhibitor KVR-1-102
Method: X-RAY DIFFRACTION / Resolution: 1.85 Å

PDB-3r1s:
CDK2 in complex with inhibitor KVR-1-127
Method: X-RAY DIFFRACTION / Resolution: 1.8 Å

PDB-3r1y:
CDK2 in complex with inhibitor KVR-1-134
Method: X-RAY DIFFRACTION / Resolution: 1.8 Å

PDB-3r28:
CDK2 in complex with inhibitor KVR-1-140
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3r6x:
CDK2 in complex with inhibitor KVR-1-158
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3r71:
CDK2 in complex with inhibitor KVR-1-162
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3r73:
CDK2 in complex with inhibitor KVR-1-164
Method: X-RAY DIFFRACTION / Resolution: 1.7 Å

PDB-3r7e:
CDK2 in complex with inhibitor KVR-1-67
Method: X-RAY DIFFRACTION / Resolution: 1.9 Å

PDB-3r7i:
CDK2 in complex with inhibitor KVR-1-74
Method: X-RAY DIFFRACTION / Resolution: 1.85 Å

PDB-3r7u:
CDK2 in complex with inhibitor KVR-1-75
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3r7v:
CDK2 in complex with inhibitor KVR-1-9
Method: X-RAY DIFFRACTION / Resolution: 1.95 Å

PDB-3r7y:
CDK2 in complex with inhibitor KVR-2-88
Method: X-RAY DIFFRACTION / Resolution: 1.9 Å

PDB-3r83:
CDK2 in complex with inhibitor KVR-2-92
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3r8l:
CDK2 in complex with inhibitor L3-4
Method: X-RAY DIFFRACTION / Resolution: 1.9 Å

PDB-3r8m:
CDK2 in complex with inhibitor L3-3
Method: X-RAY DIFFRACTION / Resolution: 1.8 Å

PDB-3r8p:
CDK2 in complex with inhibitor NSK-MC1-6
Method: X-RAY DIFFRACTION / Resolution: 1.8 Å

PDB-3rai:
CDK2 in complex with inhibitor KVR-1-160
Method: X-RAY DIFFRACTION / Resolution: 1.7 Å

PDB-3rm6:
CDK2 in complex with inhibitor KVR-2-80
Method: X-RAY DIFFRACTION / Resolution: 1.6 Å

PDB-3rm7:
CDK2 in complex with inhibitor KVR-1-91
Method: X-RAY DIFFRACTION / Resolution: 1.85 Å

PDB-3roy:
CDK2 in complex with inhibitor KVR-1-154
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

PDB-3rpo:
CDK2 in complex with inhibitor KVR-1-156
Method: X-RAY DIFFRACTION / Resolution: 1.75 Å

Chemicals

ChemComp-EDO:
1,2-ETHANEDIOL

ChemComp-X01:
3-(4-amino-1,3,5-triazin-2-yl)-4-hydroxybenzonitrile

ChemComp-HOH:
WATER

ChemComp-X07:
5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-X06:
4-chloro-2-(4,6-diamino-1,3,5-triazin-2-yl)phenol

ChemComp-PO4:
PHOSPHATE ION

ChemComp-X0A:
2-[4-amino-6-(phenylamino)-1,3,5-triazin-2-yl]-4-chlorophenol

ChemComp-X11:
2-(4,6-diamino-1,3,5-triazin-2-yl)phenol

ChemComp-X03:
(5R)-5-(2-methylbutan-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide

ChemComp-X14:
(5R)-5-(2-methylbutan-2-yl)-N-(4-sulfamoylbenzyl)-4,5,6,7-tetrahydro-2H-indazole-3-carboxamide

ChemComp-X19:
(5S)-N-methyl-5-(2-methylbutan-2-yl)-4,5,6,7-tetrahydro-2H-indazole-3-carboxamide

ChemComp-X6A:
2-{[(2-aminopyrimidin-5-yl)methyl]amino}-4-chloro-5-nitrobenzamide

ChemComp-X62:
4-chloro-2-{[(2-chloropyrimidin-5-yl)methyl]amino}-5-nitrobenzamide

ChemComp-X63:
2-{[(2-aminopyrimidin-5-yl)methyl]amino}-4-[(2-hydroxyethyl)amino]-5-nitrobenzamide

ChemComp-X4B:
4-chloro-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-X65:
5-nitro-2-[(4-sulfamoylbenzyl)amino]benzamide

ChemComp-X66:
2-(4,6-diamino-1,3,5-triazin-2-yl)benzene-1,4-diol

ChemComp-X67:
2-(4,6-diamino-1,3,5-triazin-2-yl)-4-fluorophenol

ChemComp-X69:
4-methoxy-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-X72:
4-chloro-5-nitro-2-[(pyrimidin-5-ylmethyl)amino]benzamide

ChemComp-X75:
4-chloro-2-{[(6-chloropyridin-3-yl)methyl]amino}-5-nitrobenzamide

ChemComp-X73:
2-{[(6-chloropyridin-3-yl)methyl]amino}-5-nitrobenzamide

ChemComp-X76:
2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-XA0:
4-chloro-5-nitro-2-[(3,4,5-trifluorobenzyl)amino]benzamide

ChemComp-X84:
4-[(3-hydroxypropyl)amino]-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-X86:
4-[(3-methoxypropyl)amino]-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-X87:
4-[(3-aminopropyl)amino]-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-X88:
5-nitro-2-[(pyrazin-2-ylmethyl)amino]benzamide

ChemComp-X9I:
4-{[(2-carbamoyl-4-nitrophenyl)amino]methyl}benzoic acid

ChemComp-X96:
2-{[4-(aminomethyl)benzyl]amino}-5-nitrobenzamide

ChemComp-Z02:
5-nitro-2-[(pyridin-2-ylmethyl)amino]benzamide

ChemComp-Z04:
2-{[(2-aminopyrimidin-5-yl)methyl]amino}-4-(morpholin-4-yl)-5-nitrobenzamide

ChemComp-Z14:
4-(4-aminopiperidin-1-yl)-2-{[(2-aminopyrimidin-5-yl)methyl]amino}-5-nitrobenzamide

ChemComp-Z30:
(5R)-5-tert-butyl-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide

ChemComp-Z19:
1H-indazole-3-carbohydrazide

ChemComp-Z46:
(5R)-5-propyl-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide

ChemComp-X85:
4-{[3-(morpholin-4-yl)propyl]amino}-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-18Z:
2-{[(2-aminopyrimidin-5-yl)methyl]amino}-5-nitro-4-{[2-(piperazin-1-yl)ethyl]amino}benzamide

ChemComp-19Z:
2-[(4-hydroxybenzyl)amino]-5-nitrobenzamide

ChemComp-22Z:
4-(hexylamino)-5-nitro-2-[(pyridin-3-ylmethyl)amino]benzamide

ChemComp-24Z:
4-({4-carbamoyl-2-nitro-5-[(pyridin-3-ylmethyl)amino]phenyl}amino)butanoic acid

Source
  • homo sapiens (human)
KeywordsTRANSFERASE/TRANSFERASE INHIBITOR / protein kinase / inhibitor / TRANSFERASE-TRANSFERASE INHIBITOR complex

+
About Yorodumi Papers

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242)：Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi Papers

Database of articles cited by EMDB/PDB/SASBDB data

  • Database of articles cited by EMDB, PDB, and SASBDB entries
  • Using PubMed data

Related info.:EMDB / PDB / SASBDB / Yorodumi / EMN Papers / Changes in new EM Navigator and Yorodumi

Read more